Opinion|Videos|March 28, 2025
Optimizing First-Line and Sequential Therapy in Advanced NSCLC
Author(s)Eric K. Singhi, M.D., Ben Creelan, M.D.
Panelists discuss how biomarkers like PD-L1 guide first-line therapy in advanced non-small cell lung cancer (NSCLC), with higher expression favoring PD-1 inhibitors. Other factors like performance status and comorbidities also support their use. Post progression, PD-1 inhibitors are often used alone or in combination for subsequent lines of treatment.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What role do biomarkers like PD-L1 play in determining first-line therapy options for advanced NSCLC, and how does level of expression impact initial drug choice?
- What other patient characteristics influence initial treatment choices in advanced NSCLC, and how do they support using PD-1s as first-line options?
- Following disease progression on initial therapy, how frequently are PD-1 inhibitors used alone or in combination for subsequent lines of treatment?
Advertisement
Related to this article
The rule requires pharmacy benefit managers to disclose rebates and discounts, money made from spread pricing and incentives for formulary placement.
As pulmonary fibrosis treatment options grow, Rachael Prusi of Prime Therapeutics says health plans should lean on guidelines and strong case management.
Patients with pulmonary fibrosis wait about two years for a diagnosis. Rachael Prusi of Prime Therapeutics explains how health plans can find them sooner.
The FDA has approved three HIV products since June 2025, and the late-stage pipeline is testing how far apart doses can be spaced. Here are the milestones payers and health systems should track through 2027.
Hiva Pourarsalan at AMCP Nexus explains how MFP shifts Medicare drug pricing, disrupting rebates and contracting and forcing payers to rethink formularies.
EHRs miss many cancer deaths. Linking electronic health records with claims and third‑party death data sharply improves accuracy, Tempus reports at AMCP Nexus.
CMS projects roughly 2.3 million people will lose Medicaid coverage in 2027 under the new community engagement requirements, also referred to as work requirements: four in ten to paperwork, not noncompliance. Arkansas showed how that happens; here is what plans can learn before the clock starts.
Managed care leaders should vet AI tools before use and recheck them over time, and pharmacists need AI literacy, according to two AMCP Nexus 2026 presenters.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
5 things you should know about the midterms and healthcare
2
2.3 million reasons to rethink member communications before Jan. 1
3
5 things you should know about intismeran, the Moderna-Merck cancer vaccine
4
Prime's Pat Gleason flags cost, timing gaps in type 1 diabetes screening | AMCP Nexus 2026
5